Brixadi extended-release injection for subcutaneous use is now available in the U.S. for the treatment of moderate to severe opioid use disorder
Braeburn announces that Brixadi (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine, is now available in the U.S.
Brixadi should be used as part of a complete treatment plan that includes counseling and psychosocial support.
Brixadi is the first and only injectable buprenorphine for the treatment of moderate to severe OUD that offers weekly and monthly doses. Patients currently being treated with oral buprenorphine-containing products can be switched directly to either Brixadi Weekly or Brixadi Monthly in accordance with equivalent doses suggested in the Prescribing Information for Brixadi.
Brixadi is the only buprenorphine injectable that utilizes FluidCrystal Injection Depot Technology, allowing for a low volume pre-filled syringe with a thin needle. Upon injection and contact with fluids in the tissue, the solution transforms into a nanostructured liquid-crystalline gel allowing for a slow release of buprenorphine at a steady rate over a one-week or one-month period. Brixadi is delivered with a 23-gauge needle and may be administered in the buttock, thigh, stomach (abdomen) or upper arm. Brixadi does not require refrigeration.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins